神経調節の市場：タイプ（内部（深部脳刺激、迷走神経刺激）、外部（経頭蓋磁気刺激））、アプリケーション（パーキンソン病、うつ病、尿失禁、てんかん、肥満）別 - 2027年までの世界予測

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

神経調節の世界市場は、2022年に推定60億米ドルと評価され、予測期間中に11.8%のCAGRで2027年までに104億米ドルに達すると予測されています。市場の成長は、パーキンソン病の罹患率の上昇、尿失禁の発生率の高さ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年8月4日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	207	246	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

神経調節の世界市場は、2022年に推定60億米ドルと評価され、予測期間中に11.8%のCAGRで2027年までに104億米ドルに達すると予測されています。市場の成長は、パーキンソン病の罹患率の上昇、尿失禁の発生率の高さ、医療における外部神経調節の広範な使用、低コストと使いやすさがこの市場の成長を妨げる主要因であることなどの要因によってもたらされます。
"神経調節市場の製品別成長率では、予測期間中、内部神経調節セグメントが最も高い成長率を占めた"
神経調節市場は、内部神経調節と外部神経調節に区分されます。予測期間中は、内部神経調節が最も高い成長率を記録すると予想されます。低侵襲性、身体的影響の軽減、生活の質の向上などの要因が、このセグメントの成長に寄与しています。
"深部脳刺激療法セグメントが最高のCAGRを占めた"
内部神経調節市場は、タイプに基づいて、脊髄刺激（SCS）、脳深部刺激（DBS）、迷走神経刺激（VNS）、仙骨神経刺激（SNS）、胃電気刺激（GES）に区分される。脳深部刺激療法は、副作用を減らすために刺激パラメータを変更できる低侵襲技術であるため、予測期間中に最も高い成長率を記録すると予想されます。
"アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想される"
世界の神経調節市場は、北米、欧州、アジア太平洋地域、その他の地域の5地域に区分されます。アジア太平洋地域は、予測期間中に神経調節市場で最も高い成長を遂げると予想されています。この地域の高成長は、主に老年人口の増加、高齢者層における神経障害の高い疾病負担に起因しています。
本レポートのために実施した主なインタビューは、以下のように分類されます。

- 企業タイプ別。企業タイプ別：Tier 1 28%、Tier 2 42%、Tier 3 30
- 役職別Cレベル：30％、Dレベル：34％、その他：36
- 地域別北米：46%、欧州：25%、アジア太平洋：18%、その他の地域：11
レポート掲載企業リスト

- メドトロニック (アイルランド)
- ボストン・サイエンティフィック・コーポレーション（米国）
- アボット・ラボラトリーズ（米国）
- リヴァノヴァ（英国）
- ニューロペース社（米国）
- ニューロネティクス（米国）
- ヘリウス・メディカル・テクノロジーズ（米国）
- レニショー (英国)
- GTXメディカル (オランダ)
- バイオインダクション（英国）
- バイオネス（米国）
- ネブロ社（米国）
- ブルーウィンドメディカル（イスラエル）
- アレバ・ニューロセラピューティック（スイス）
- ジーメル・メディカル（台湾）
- ニューロシグマ社（米国）
- バイオウェーブゴーUSA（米国）
- シナプスバイオメディカル社（米国）
- カーディオノミック（米国）
- セラニカバイオエレクトロニクス (イスラエル)
- マイクロトランスポンダー（米国）
- ソテリックスメディカル (米)
- サルーダメディカル (米国)
- エレクトロコア社(米国)
- tVNSテクノロジーズ(ドイツ)

調査対象
本レポートでは、世界の神経調節市場の詳細な実態を把握することができます。タイプ、アプリケーション、地域などの異なるセグメントにおける市場規模や将来の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイル、最近の開発、主要な市場戦略とともに、詳細な競合分析も行っています。

レポート購入の主なメリット
本レポートは、神経調節市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 33
1.3.1 NEUROMODULATION MARKET SEGMENTATION 33
1.3.2 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Secondary sources 38
2.1.2 PRIMARY DATA 38
2.1.2.1 Key data from primary sources 39
2.1.2.2 Key industry insights 40
TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 40
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 41
2.2.1 BOTTOM-UP APPROACH 42
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 42
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 43
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 6 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ANALYSIS 45
2.5 ASSUMPTIONS 45
2.6 RISK ASSESSMENT 45
TABLE 2 RISK ASSESSMENT: NEUROMODULATION MARKET 45
2.7 LIMITATIONS 46
2.7.1 METHODOLOGY-RELATED LIMITATIONS 46
2.7.2 SCOPE-RELATED LIMITATIONS 46

3 EXECUTIVE SUMMARY 47
FIGURE 7 NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 47
FIGURE 8 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 48
FIGURE 9 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 48
FIGURE 10 NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT 49
4 PREMIUM INSIGHTS 50
4.1 NEUROMODULATION MARKET OVERVIEW 50
FIGURE 11 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET 50
4.2 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021) 50
FIGURE 12 INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 50
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET 51
FIGURE 13 COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 14 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries 53
5.2.1.2 Growing focus on neuromodulation & neurostimulation technologies 53
5.2.1.3 Expanding applications of neuromodulation 54
TABLE 3 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS 54
FIGURE 15 RESEARCH PAPERS PUBLISHED (2011–2021) 55
5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders 55
5.2.1.5 Government support for research on neurological disorders 56
FIGURE 16 FUNDING FOR RESEARCH BY NIH (US) 56
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of neuromodulation procedures 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Emerging economies 57
FIGURE 17 GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012–2019 57
5.2.4 CHALLENGES 58
5.2.4.1 Stringent regulatory frameworks and time-consuming approval processes 58
5.2.4.2 Preference for drug therapies over neuromodulation products 58
5.2.4.3 Shortage of trained professionals 58
5.2.4.4 Product recalls 58
TABLE 4 MAJOR PRODUCT RECALLS 59
5.3 SCENARIO-BASED MARKET ASSESSMENT 60
5.3.1 NEUROMODULATION MARKET 60
FIGURE 18 PESSIMISTIC SCENARIO 60
FIGURE 19 OPTIMISTIC SCENARIO 60
FIGURE 20 REALISTIC SCENARIO 61
5.4 VALUE CHAIN ANALYSIS 61
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 62
5.4.1 RESEARCH & DEVELOPMENT 62
5.4.2 MANUFACTURING & ASSEMBLY 62
5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 62
5.5 SUPPLY CHAIN ANALYSIS 63
FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63
5.6 TECHNOLOGY ANALYSIS 64
5.7 PORTER’S FIVE FORCES ANALYSIS 64
5.7.1 THREAT FROM NEW ENTRANTS 65
5.7.2 INTENSITY OF COMPETITIVE RIVALRY 65
5.7.3 BARGAINING POWER OF BUYERS 65
5.7.4 BARGAINING POWER OF SUPPLIERS 65
5.7.5 THREAT FROM SUBSTITUTES 65
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.8.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 66
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY 66
TABLE 5 INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%) 66
5.8.2 BUYING CRITERIA 66
FIGURE 24 KEY BUYING CRITERIA FOR TOP 2 END USERS 66
TABLE 6 KEY BUYING CRITERIA, BY END USER 67
5.9 REGULATORY LANDSCAPE 67
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION 67
5.9.1 BY REGION 68
5.9.1.1 North America 68
5.9.1.2 Europe 68
5.9.1.3 Asia Pacific 69
5.9.1.3.1 India 69
5.9.1.3.2 China 69
5.10 PATENT ANALYSIS 69

5.11 KEY CONFERENCES AND EVENTS IN 2022 70
TABLE 8 LIST OF CONFERENCES & EVENTS 70
5.12 PRICING ANALYSIS 71
TABLE 9 PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES 71
5.13 TRADE ANALYSIS 72
TABLE 10 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION) 72
TABLE 11 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION) 72
5.14 ECOSYSTEM ANALYSIS 73
5.14.1 ROLE IN ECOSYSTEM 73
5.14.2 KEY PLAYERS IN THE NEUROMODULATION MARKET 74
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
6 NEUROMODULATION MARKET, BY TYPE 75
6.1 INTRODUCTION 76
TABLE 12 NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 76
6.2 INTERNAL NEUROMODULATION 76
TABLE 13 INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 14 INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 15 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 16 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 17 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 18 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 78
6.2.1 SPINAL CORD STIMULATION 79
6.2.1.1 Growing incidence of spinal cord injuries to support market growth 79
TABLE 19 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 20 SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 80
TABLE 21 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 22 EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 23 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 24 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 81
6.2.2 DEEP BRAIN STIMULATION 82
6.2.2.1 DBS allows stimulation parameters to be changed to reduce side effects 82
TABLE 25 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 26 DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 83
TABLE 27 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 28 EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 29 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 30 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 84
6.2.3 VAGUS NERVE STIMULATION 84
6.2.3.1 Non-invasive vagus nerve stimulation does not require surgical implantation—a key benefit 84
TABLE 31 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 32 VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 85
TABLE 33 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 34 EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 35 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 36 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 86
6.2.4 SACRAL NERVE STIMULATION 87
6.2.4.1 Widening scope of sacral nerve stimulation to drive growth 87
TABLE 37 SACRAL NERVE STIMULATION DEVICES OFFERED 87
TABLE 38 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 39 SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 88
TABLE 40 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 41 EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 42 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 43 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 89
6.2.5 GASTRIC ELECTRICAL STIMULATION 89
6.2.5.1 Growing number of people suffering from severe GERD and gastroparesis to fuel market growth 89
TABLE 44 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 45 GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 90
TABLE 46 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 47 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 48 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 49 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 91
6.3 EXTERNAL NEUROMODULATION 92
TABLE 50 EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 51 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 52 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 53 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 54 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 55 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 93
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION 94
6.3.1.1 Extensive use in healthcare, low cost, and ease of use to favor market growth 94
TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 57 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 95
TABLE 58 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 59 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 60 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 61 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 96
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION 96
6.3.2.1 Minimal patient discomfort associated with TMS supports demand 96
TABLE 62 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 63 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 97
TABLE 64 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 65 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 66 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 67 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 98

6.3.3 RESPIRATORY ELECTRICAL STIMULATION 99
6.3.3.1 High treatment efficacy to fuel market growth 99
TABLE 68 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 69 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS) 99
TABLE 70 NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 71 EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 72 ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 73 REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 101
7 NEUROMODULATION MARKET, BY APPLICATION 102
7.1 INTRODUCTION 103
7.2 SPINAL CORD STIMULATION MARKET, BY APPLICATION 103
TABLE 74 SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103
7.2.1 CHRONIC PAIN 103
7.2.1.1 High incidence of chronic pain supports market growth 103
TABLE 75 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020–2027 (USD MILLION) 103
7.2.2 FAILED BACK SURGERY SYNDROME 104
7.2.2.1 Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies 104
TABLE 76 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020–2027 (USD MILLION) 104
7.2.3 ISCHEMIA 104
7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth 104
TABLE 77 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION) 105
7.3 DEEP BRAIN STIMULATION MARKET, BY APPLICATION 105
TABLE 78 DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105
7.3.1 PARKINSON’S DISEASE 105
7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D activity in this area to drive growth 105
TABLE 79 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION) 106
7.3.2 TREMORS 106
7.3.2.1 High efficacy of DBS in treating tremors boosts demand 106
TABLE 80 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020–2027 (USD MILLION) 106

7.3.3 DEPRESSION 107
7.3.3.1 Lack of evidence of efficacy of DBS for depression treatment to limit market growth 107
TABLE 81 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION) 107
7.3.4 OTHER DBS APPLICATIONS 107
TABLE 82 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 108
7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION 108
TABLE 83 SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108
7.4.1 URINE INCONTINENCE 108
7.4.1.1 High incidence of urine incontinence offers growth opportunities 108
TABLE 84 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020–2027 (USD MILLION) 109
7.4.2 FECAL INCONTINENCE 109
7.4.2.1 Reduced symptom recurrence supports use of SNS in fecal incontinence treatment 109
TABLE 85 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020–2027 (USD MILLION) 109
7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION 110
TABLE 86 VAGUS NERVE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
7.5.1 EPILEPSY 110
7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market 110
TABLE 87 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020–2027 (USD MILLION) 110
7.5.2 OTHER VNS APPLICATIONS 110
TABLE 88 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 111
7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION 111
TABLE 89 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 111
7.6.1 GASTROPARESIS 111
7.6.1.1 GES treatment reduces hospitalizations for patients affected by gastroparesis 111
TABLE 90 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020–2027 (USD MILLION) 112
7.6.2 OBESITY 112
7.6.2.1 Risks associated with gastric bypass to increase preference for GES 112
TABLE 91 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION) 112
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION 113
TABLE 92 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 113

7.7.1 TREATMENT-RESISTANT DEPRESSION 113
7.7.1.1 TENS induces relaxed state in patients suffering from treatment-resistant depression 113
TABLE 93 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020–2027 (USD MILLION) 113
7.7.2 OTHER TENS APPLICATIONS 113
TABLE 94 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 114
7.8 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION 114
TABLE 95 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
7.8.1 DEPRESSION 114
7.8.1.1 Increased acceptance among patients to drive demand for TMS 114
TABLE 96 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION) 115
7.8.2 MIGRAINE 115
7.8.2.1 High prevalence of migraine to support market growth 115
TABLE 97 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020–2027 (USD MILLION) 115
7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION 116
7.9.1 SPINAL CORD INJURY 116
7.9.1.1 Rising incidence of spinal cord injuries ensures sustained demand for RES 116
TABLE 98 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020–2027 (USD MILLION) 116
8 NEUROMODULATION MARKET, BY REGION 117
8.1 INTRODUCTION 118
TABLE 99 NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 118
8.2 NORTH AMERICA 118
FIGURE 25 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT 119
TABLE 100 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 101 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 102 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 103 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 104 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 105 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 106 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 107 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 108 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 109 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 110 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
8.2.1 US 123
8.2.1.1 Large number of prominent players makes US the largest market 123
TABLE 111 US: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 112 US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 113 US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
8.2.2 CANADA 125
8.2.2.1 Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation 125
TABLE 114 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA 126
TABLE 115 CANADA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 116 CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 117 CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
8.3 EUROPE 127
TABLE 118 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 119 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 120 EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 121 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 122 EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 123 EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 124 EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 125 EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 126 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 127 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 128 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
8.3.1 GERMANY 131
8.3.1.1 Favorable government initiatives ensure strong market growth in Germany 131
TABLE 129 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 130 GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 131 GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
8.3.2 UK 133
8.3.2.1 High public- and private-sector investments fuel market growth 133
TABLE 132 UK: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 133 UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 134 UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
8.3.3 FRANCE 135
8.3.3.1 Availability of insurance and favorable healthcare reforms contribute to growth 135
TABLE 135 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 136 FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 137 FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
8.3.4 ITALY 136
8.3.4.1 Easy access to healthcare services makes Italy a lucrative market 136
TABLE 138 ITALY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 139 ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 140 ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
8.3.5 SPAIN 137
8.3.5.1 Growing government initiatives may support market growth in Spain 137
TABLE 141 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 142 SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 143 SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
8.3.6 REST OF EUROPE 138
TABLE 144 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050 139
TABLE 145 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 146 REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 147 REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
8.4 ASIA PACIFIC 140
FIGURE 26 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT 141
TABLE 148 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 149 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 150 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 151 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 152 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 153 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 154 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 155 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
TABLE 157 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
TABLE 158 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
8.4.1 JAPAN 145
8.4.1.1 Japan dominates the APAC market for neuromodulation 145
TABLE 159 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 160 JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 161 JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
8.4.2 CHINA 146
8.4.2.1 Growing geriatric population will favor market growth in China 146
TABLE 162 CHINA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 163 CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 164 CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
8.4.3 INDIA 148
8.4.3.1 Improvements in healthcare infrastructure in the country will support market 148
TABLE 165 INDIA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 166 INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 167 INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 149

8.4.4 REST OF ASIA PACIFIC 149
TABLE 168 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 169 REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 170 REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
8.5 REST OF THE WORLD 151
TABLE 171 REST OF THE WORLD: NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION) 151
TABLE 172 REST OF THE WORLD: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 173 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 174 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 175 REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 176 REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 177 REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 178 REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 179 REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 180 REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 181 REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
8.5.1 LATIN AMERICA 154
8.5.1.1 Latin America holds largest share of neuromodulation market in RoW 154
TABLE 182 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 183 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 184 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
8.5.2 MIDDLE EAST & AFRICA 156
8.5.2.1 High cost of neuromodulation to hamper market growth 156
TABLE 185 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 186 MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 187 MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 157

9 COMPETITIVE LANDSCAPE 158
9.1 OVERVIEW 158
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 158
TABLE 188 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 158
9.3 REVENUE SHARE ANALYSIS 159
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET 159
9.4 MARKET SHARE ANALYSIS 160
TABLE 189 NEUROMODULATION MARKET: DEGREE OF COMPETITION 160
9.5 COMPANY EVALUATION MATRIX 161
9.5.1 STARS 161
9.5.2 EMERGING LEADERS 161
9.5.3 PERVASIVE PLAYERS 161
9.5.4 PARTICIPANTS 161
FIGURE 28 COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET 162
9.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 162
9.6.1 PROGRESSIVE COMPANIES 162
9.6.2 STARTING BLOCKS 162
9.6.3 RESPONSIVE COMPANIES 163
9.6.4 DYNAMIC COMPANIES 163
FIGURE 29 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET 163
9.7 COMPANY FOOTPRINT ANALYSIS 164
TABLE 190 OVERALL FOOTPRINT OF COMPANIES 164
TABLE 191 REGIONAL FOOTPRINT OF COMPANIES 165
TABLE 192 TYPE FOOTPRINT OF COMPANIES 166
9.8 COMPETITIVE BENCHMARKING 167
TABLE 193 NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES 167
9.9 COMPETITIVE SCENARIO 167
9.9.1 PRODUCT LAUNCHES & APPROVALS 167
TABLE 194 KEY PRODUCT LAUNCHES & APPROVALS 167
9.9.2 DEALS 168
TABLE 195 KEY DEALS 168
9.9.3 OTHER DEVELOPMENTS 169
TABLE 196 OTHER KEY DEVELOPMENTS 169

10 COMPANY PROFILES 170
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS 170
10.1.1 MEDTRONIC PLC 170
TABLE 197 MEDTRONIC PLC: BUSINESS OVERVIEW 170
FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT (2021) 171
10.1.2 BOSTON SCIENTIFIC CORPORATION 175
TABLE 198 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 175
FIGURE 31 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021) 176
10.1.3 ABBOTT LABORATORIES 179
TABLE 199 ABBOTT LABORATORIES: BUSINESS OVERVIEW 179
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 180
10.1.4 LIVANOVA PLC 182
TABLE 200 LIVANOVA PLC: BUSINESS OVERVIEW 182
FIGURE 33 LIVANOVA PLC: COMPANY SNAPSHOT (2021) 183
10.1.5 NEVRO CORPORATION 185
TABLE 201 NEVRO CORPORATION: BUSINESS OVERVIEW 185
FIGURE 34 NEVRO CORPORATION: COMPANY SNAPSHOT (2021) 185
10.1.6 NEUROSIGMA, INC. 187
TABLE 202 NEUROSIGMA, INC.: BUSINESS OVERVIEW 187
10.1.7 NEUROPACE, INC. 189
TABLE 203 NEUROPACE, INC.: BUSINESS OVERVIEW 189
FIGURE 35 NEUROPACE, INC.: COMPANY SNAPSHOT (2021) 189
10.1.8 SOTERIX MEDICAL INC. 192
TABLE 204 SOTERIX MEDICAL INC.: BUSINESS OVERVIEW 192
10.1.9 SYNAPSE BIOMEDICAL INC. 194
TABLE 205 SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW 194
10.1.10 ALEVA NEUROTHERAPEUTICS SA 195
TABLE 206 ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW 195
10.1.11 THERANICA BIO-ELECTRONICS LTD. 196
TABLE 207 THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW 196
10.1.12 NEURONETICS 197
TABLE 208 NEURONETICS: BUSINESS OVERVIEW 197
FIGURE 36 NEURONETICS: COMPANY SNAPSHOT (2021) 198
10.1.13 BIONESS 200
TABLE 209 BIONESS: BUSINESS OVERVIEW 200
10.1.14 BIOINDUCTION 201
TABLE 210 BIOINDUCTION: BUSINESS OVERVIEW 201

10.2 OTHER PLAYERS 202
10.2.1 GIMER MEDICAL 202
10.2.2 GTX MEDICAL 202
10.2.3 HELIUS MEDICAL TECHNOLOGIES 203
10.2.4 MICROTRANSPONDER 203
10.2.5 BLUEWIND MEDICAL 204
10.2.6 ELECTROCORE, INC. 204
10.2.7 RENISHAW PLC 205
10.2.8 TVNS TECHNOLOGIES GMBH 205
10.2.9 BIOWAVEGO USA 206
10.2.10 CARDIONOMIC, INC. 206
10.2.11 SALUDA MEDICAL PTY LTD. 206
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 207
11.1 DISCUSSION GUIDE 207
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 212
11.3 AVAILABLE CUSTOMIZATIONS 214
11.4 RELATED REPORTS 214
11.5 AUTHOR DETAILS 215

ページTOPに戻る

Table of Contents

Summary

The global neuromodulation market is valued at an estimated USD 6.0 billion in 2022 and is projected to reach USD 10.4 billion by 2027, at a CAGR of 11.8% during the forecast period. Market growth is driven by factors such as the growing incidence of rising incidence of Parkinson’s disease, high incidence of urine incontinence, extensive use of external neuromodulation in healthcare, low cost and ease of use are the major factors hampering the growth of this market.
“The internal neuromodulation segment accounted for the highest growth rate in the neuromodulation market, by product, during the forecast period”
The neuromodulation market is segmented into Internal neuromodulation and external neuromodulation. The internal neuromodulation is expected to register the highest growth rate during the forecast period. Factors such as the minimally invasive nature, reduced physical impact and improved quality of life are contributing to the growth of this segment.
“Deep Brain Stimulation segment accounted for the highest CAGR”
Based on type, the internal neuromodulation market is segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). Deep brain stimulation segment is expected to register highest growth rate during forecast period as DBS is a minimally invasive technique that allows the stimulation parameters to be changed to reduce side effects.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global neuromodulation market is segmented into five regions - North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is expected to witness the highest growth in the neuromodulation market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of neurological disorders among senior population
The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 28%, Tier 2 - 42%, and Tier 3 - 30%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 46%, Europe - 25%, Asia Pacific - 18%, and the Rest of the World – 11%
Lists of Companies Profiled in the Report:

• Medtronic (Ireland)
• Boston Scientific Corporation (US)
• Abbott Laboratories (US)
• LivaNova (UK)
• NeuroPace (US)
• Neuronetics (US)
• Helius Medical Technologies (US)
• Renishaw (UK)
• GTX Medical (Netherlands)
• Bioinduction (UK)
• Bioness (US)
• Nevro Corporation (US)
• BlueWind Medical (Israel)
• Aleva Neurotherapeutics (Switzerland)
• GiMer Medical (Taiwan)
• NeuroSigma (US)
• BioWaveGo USA (US)
• Synapse Biomedical (US)
• Cardionomic (US)
• Theranica Bio-Electronics (Israel)
• MicroTransponder (US)
• Soterix Medical (US)
• Saluda Medical (US)
• Electrocore, Inc. (US)
• tVNS Technologies (Germany).

Research Coverage:
This report provides a detailed picture of the global neuromodulation market. It aims at estimating the size and future growth potential of the market across different segments, such as type, application and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall neuromodulation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（parkinsons disease）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

神経調節の市場：タイプ（内部（深部脳刺激、迷走神経刺激）、外部（経頭蓋磁気刺激））、アプリケーション（パーキンソン病、うつ病、尿失禁、てんかん、肥満）別 - 2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（parkinsons disease）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?